Summary

GLP-1 is secreted in response to food ingestion, although the action of glucagon-like peptide–1 on brain glucose metabolism has been hypothesized but has not yet been established. This article presents results from the Effect of Exenatide on Brain, Adipose Tissue, Pancreas, and Liver Function study [NCT01588418], a phase 4 clinical trial that aimed to evaluate the effect of a single injection of exenatide (a GLP-1 agonist) on cerebral glucose metabolism during an oral glucose tolerance test.